Color keeps GSK generic off the market

Share this article:
Color keeps GSK generic off the market
Sandoz's AirFluSal Forspiro

A purple casing is keeping Sandoz from being able to market its generic of GlaxoSmithKline's COPD drug Advair in Germany.

The Wall Street Journal reports that GSK filed a preliminary injunction against the Novartis generics division because the Sandoz inhaler for its AirFluSal Forspiro inhaler is purple, just like the inhaler for GSK's Advair (known as Seretide and Viani), claiming unfair competition.

"Glaxo says it believes customers recognize the color purple as indicating its own product and Forspiro's appearance could lead to confusion among patients, pharmacists and healthcare providers,” reports the WSJ.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.